Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Researchers identify key protein that can reduce severity of disease equivalent to MS in mice

In multiple sclerosis, the immune system goes rogue, improperly attacking the body's own central nervous system. Mobility problems and cognitive impairments may arise as the nerve cells become damaged.

12 Nov 2014

Study points to major role of obesity in triggering, prolonging autoimmune diseases

Autoimmune diseases like Crohn's Disease and multiple sclerosis, in which the immune system attacks its own body rather than predatory invaders, affect 5-20% of the global community. A study published recently in Autoimmunity Reviews by Prof. Yehuda Shoenfeld, the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases at Tel Aviv University's Sackler Faculty of Medicine and Head of Zabludowicz Center for Autoimmune Diseases at Chaim Sheba Medical Center, Tel Hashomer, points to the major role obesity plays in triggering and prolonging these autoimmune diseases.

11 Nov 2014

U of T, Chematria and IBM partner to find new treatments for Ebola virus

The University of Toronto, Chematria and IBM are combining forces in a quest to find new treatments for the Ebola virus.

11 Nov 2014

Living with multiple sclerosis (MS): an interview with Gretchen Rubin and Megan Weigel

Multiple sclerosis, or MS, is a chronic, often disabling disease of the central nervous system, which is made up of the brain, spinal cord, and optic nerves. Symptoms may be mild, moderate, or severe, ranging from numbness in the limbs to paralysis or loss of vision. Approximately 400,000 Americans are living with MS.

9 Nov 2014

Perrigo agrees to acquire Omega for $4.5 billion

Perrigo Company plc, a leading global provider of "Quality Affordable Healthcare Products," and Omega Pharma NV, one of the largest OTC healthcare companies in Europe, headquartered in Nazareth, Belgium, today announced that they have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for €3.6 billion, or $4.5 billion, comprised of the purchase of Omega's equity for €2.48 billion and the assumption of €1.1 billion in debt.

6 Nov 2014

Perrigo re-launches shipments of Guaifenesin 600mg Extended-Release tablets

Perrigo Company plc announced today that it has reinitiated shipments of Guaifenesin 600mg Extended-Release tablets to its retail and wholesale customers in the United States. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex 600mg Extended-Release tablets.

6 Nov 2014

Commonly prescribed drugs for arthritis and pain may increase risk of death from stroke

Commonly prescribed, older drugs for arthritis and pain may increase the risk of death from stroke, according to a study published in the November 5, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. Stroke is the fourth leading cause of death in the United States, according to the Centers for Disease Control and Prevention.

5 Nov 2014

Medical illness common in bipolar disorder

Patients with bipolar disorder have high rates of medical illness, which often exceeds the levels observed in patients with unipolar depression, show results of a UK-based study.

5 Nov 2014

Hemp Health launches CBD wellness supplements

Hemp Health Inc., a pioneer in hemp cannabidiol (CBD) products, today launched their line of CBD wellness supplements. Available in oil, spray and capsule form, Hemp Health's products offer a compelling alternative to medical marijuana. The CBD supplements provide consumers with the therapeutic ingredient in hemp while allowing them to avoid the negative mental and physical effects of marijuana.

4 Nov 2014

Study: Vitamin D deficiency more prevalent in neuromuscular conditions

A study presented at the annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine adds more credence to a growing awareness of the high prevalence of vitamin D deficiency in neuromuscular disease.

31 Oct 2014

Insilico Medicine, CCARL and Plantbiosis partner to advance research on aging

Through this unique partnership, the Baltimore-based Insilico Medicine and Lethbridge-based CCARL will provide expertise in aging research and build on the personalized medicine and drug discovery platforms OncoFinder and GeroScope to develop new systems for age-related diseases.

31 Oct 2014

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.

31 Oct 2014

New study pinpoints complex genetic origins for autoimmune diseases

Scores of autoimmune diseases afflicting one in 12 Americans — ranging from type 1 diabetes, to multiple sclerosis (MS), to rheumatoid arthritis, to asthma — mysteriously cause the immune system to harm tissues within our own bodies. Now, a new study pinpoints the complex genetic origins for many of these diseases, a discovery that may lead to better diagnosis and ultimately to improved treatments.

30 Oct 2014

High-fat, low-carb diets may help control epilepsy

Diets high in fat and low in carbohydrates, such as the ketogenic or modified Atkins diet, may reduce seizures in adults with tough-to-treat epilepsy, according to a review of the research published in the October 29, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology.

30 Oct 2014

RPC1063 drug candidate has potential to improve treatment for ulcerative colitis patients

Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute.

28 Oct 2014

InSilico Medicine, CCARL collaborate to improve personalized medicine projects in multiple sclerosis

InSilico Medicine, the company focused on drug discovery for cancer and age-related diseases, announced its investment in a research collaboration with Canada Cancer and Aging Research Laboratories, Inc. The companies will collaborate on improving decision making in clinical oncology and discovery, and personalized medicine projects in multiple sclerosis (MS).

27 Oct 2014

Research could pave way for more effective drugs to treat inflammation

Six Case Western Reserve scientists are part of an international team that has discovered two compounds that show promise in decreasing inflammation associated with diseases such as ulcerative colitis, arthritis and multiple sclerosis.

25 Oct 2014

Growth factor boosts natural defence against auto-immune diseases

Our immune system defends us from harmful bacteria and viruses, but, if left unchecked, the cells that destroy those invaders can turn on the body itself, causing auto-immune diseases like type-1 diabetes or multiple sclerosis. A molecule called insulin-like growth factor-1 (IGF-1) boosts the body's natural defence against this 'friendly fire', scientists at the European Molecular Biology Laboratory in Monterotondo, Italy, have found.

25 Oct 2014

Bariatric surgery may be risk factor for condition that causes severe headaches

Bariatric surgery may be a risk factor for a condition that causes severe headaches, according to a study published in the October 22, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology.

24 Oct 2014

YEDA and XL-protein sign deal to commercialize PASylated IFN superagonis

YEDA Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist -- PAS-YNSα8 -- which has been jointly developed by scientists at the Weizmann Institute and XL-protein.

21 Oct 2014